Myriad Weighs Separation Of Diagnostics, Drug Businesses
This article was originally published in The Gray Sheet
Executive Summary
As Myriad Genetics moves into a new phase - achieving profitability in fiscal 2008 for the first time - the company is seeking to develop a new corporate strategy to drive growth, which could include a sale or spin off of its pharma business, the firm said during its fiscal 2008 sales and earnings call Aug. 19
You may also be interested in...
Newly Independent Myriad Diagnostics Firm Will Pursue Product Acquisitions
Following completion of a spin-off of its drug business, the Myriad Genetics diagnostics group plans to spend some of its large cash reserves on product acquisitions
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”